In a report issued on July 13, Matthew Harrison from Morgan Stanley maintained a Buy rating on SAGE Therapeutics (NASDAQ: SAGE), with a price target of $228. The company’s shares closed on Friday at $168.11.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 16.7% and a 65.6% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Sarepta Therapeutics, and Editas Medicine Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for SAGE Therapeutics with a $220.88 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $195.97 and a one-year low of $59.57. Currently, SAGE Therapeutics has an average volume of 546.1K.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. Last month, Kimi Iguchi, the CFO & Treasurer of SAGE bought 800 shares for a total of $360.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
